Algotec builds OEM business
Algotec builds OEM businessIsraeli PACS software developer Algotec has signed a reseller agreement with Toshiba Medical Systems, which will be selling Algotec’s MediSurf and MediStore products in conjunction with Toshiba’s PACS
Algotec builds OEM business
Israeli PACS software developer Algotec has signed a reseller agreement with Toshiba Medical Systems, which will be selling Algotecs MediSurf and MediStore products in conjunction with Toshibas PACS offerings in the Japanese market. A first joint installation has been completed.
Other OEM channels for the company have also begun to pay dividends. Algotec, which serves as a medical imaging marketing partner with HIS firm Eclipsys (PNN 8/98), has completed its first joint installation with the Atlanta-based firm at Childrens Hospital in Columbus, OH.
In addition, Algotec has also been awarded its first large-scale PACS contract from North York General Hospital in Toronto. Implementation will take place through 2000.
The company is ramping up its North American sales and support efforts, which are handled by Algotecs Duluth, GA-based subsidiary, Algotec Inc. Five sales and support engineers are employed by Algotecs U.S. operations, and that number is expected to double by the end of 1999, according to the firm.
- Search again
- Homepage
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
